Put a dot where you think we are today.

DHT-Derived Novel Endpoints in Pivotal Trials: Where Are We?

Breakout Facilitators Only: List your stakeholder group and your group's top 3 barriers to the adoption of DHT-derived endpoints in pivotal trials.

Stakeholder: Patient and academia:
1. Lack of collaboration around publicly available info;
2. Uncertainty on whether the measure is meaningful;
3. Digital exclusion.

Industry Group:
1. Lack of clear frameworks to use (not modular, lack of building blocks);
2. Lack of clear agency guidelines (incomplete information), multi-faceted validation process (data, device, internal, external);
3. Gap between technology / clinical / pharma companies on priorities / strategic imperatives / needs (requires more market researches, stakeholders' interviews, ...).

The amount of work in terms of regulatory steps, variety of patients and cohorts, evolution of technology to maintain consistency.

Government:
1) Lack of examples of where DHTs have shown additional benefits over traditional endpoint for patient benefit;
2) Do the new measurements add variability or reduce it; is the new measurement more precise?;
3) Lack of understanding of how a DHT-endpoint relates to a meaningful concept of interest to patients?

Alignment on strategic priorities at the executive level between multiple stakeholders and competing priorities in conducting clinical trials.

Government:
... 3) Lack of understanding of how a DHT-endpoint relates to a meaningful concept of interest to patients?

Government:
... 3) Lack of understanding of how a DHT-endpoint relates to a meaningful concept of interest to patients?

Lack of collaboration; lack of guidance by health authorities; challenge to get stakeholders together within companies.

Government:
... 3) Lack of understanding of how a DHT-endpoint relates to a meaningful concept of interest to patients?
Breakout Facilitators Only: List your stakeholder group and your group's top 3 barriers to the adoption of DHT-derived endpoints in pivotal trials.

INDUSTRY: 1. Amount of work to make it happen; 2. Importance of executive alignment between stakeholders; 3. Gap between tech / clinical / pharma companies on mutual understanding.
What or who do you feel plays the biggest role in unlocking the adoption of DHT-Derived Endpoints?